Discovery of a new drug to combat recurring malaria

Recurring malaria is most common in Sub-Saharan Africa affecting mainly children. Globally, 8.5 million people are ill annually, hence, generating a challenge in order to eradicate the parasite. In order to overcome this, a drug named tafenoquine is produced which enables the removal of the parasite from the liver preventing recurring of the disease.
Tafenoquine has obtained Food and Drug Administration (FDA) in the United States, however, the drugs has indicated a few side effects as in can cause severe anemia in people with enzymatic problems.